Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV

aGilead Sciences, Inc, Foster City

bQuest Clinical Research, San Francisco, California

cDP Clinical, Rockville, Maryland

dMerck & Co, Inc, Kenilworth, New Jersey

eKCAS Bioanalytical & Biomarker Services, Shawnee, Kansas, USA.

Correspondence to Felicia L. Sterman, MD, Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404, USA. E-mail: [email protected]

Received 30 September, 2022

Revised 6 February, 2023

Accepted 8 February, 2023

留言 (0)

沒有登入
gif